重大事件
外國發行人報告
6-K
2026-07-30
Cellectis宣布8月6日收市後公布2026年第二季度業績
AI 繁中摘要
📋 申報類型：6-K（外國私人發行人）
🎯 事件重點：Cellectis（納斯達克：CLLS；Euronext Growth：ALCLS）宣布將於2026年8月6日（星期四）美國市場收市後公布2026年第二季度（截至6月30日）財務業績。
📄 相關安排：業績新聞稿將於公司網站「投資者關係」頁面發布；公司是次不會舉行電話會議，投資者如有疑問，可透過電郵聯繫投資者關係團隊。
🏢 公司簡介：Cellectis 屬臨床階段生物科技企業，以開創性基因編輯平台開發細胞及基因療法。其核心策略係採用異體（allogeneic）方法開發 CAR T 免疫療法，主打「現成、即用」嘅基因編輯 CAR T 細胞用於癌症治療；同時亦有平台開發其他治療領域嘅基因療法。公司具備自家製造能力，係少數能夠由研發到生產全面控制價值鏈嘅基因編輯公司之一。總部位於法國巴黎，並於紐約及北卡羅來納州設有據點。
📊 對投資者嘅潛在影響：今次公告屬業績發布日期嘅預告，並無包含任何實際財務數字。投資者應留意公司屆時公布嘅第二季度營運表現、現金狀況、研發進度及臨床試驗更新。考慮到公司目前仍處於臨床階段，未有產品上市收入，資金消耗率及融資計劃將係市場關注焦點；加上未有季度電話會議，市場或會更側重新聞稿內容及後續投資者查詢回應。建議持倉或關注該股嘅投資者預留時間喺8月6日收市後留意相關公布。
展開英文正文
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1 Cellectis to Report Second Quarter Financial Results on August 6, 2026 NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at [email protected] About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X. For further information on Cellectis, please contact: Media contacts:Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, [email protected] Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact:Arthur Stril, Chief Financial Officer & Chief Business Officer, [email protected] Attachment Q2 2026 announcement PR_ENGLISH (https://ml.globenewswire.com/Resource/Download/f560a55d-b231-4ae6-b032-b17f8846ec16)